Semaglutide, liraglutide, and their effects beyond diabetes/obesity
The field of reverse cardio-oncology examines how subclinical and overt cardiometabolic dysfunction-such as obesity-fuels breast cancer (BCa) risk and altered tumour biology through shared mechanisms such as chronic inflammation, hormonal dysregulation, and cellular senescence. Limitations …
People with type 2 diabetes in Asia have heterogeneous phenotypes but share common features of young age-at-diagnosis, low body mass index, low pancreatic beta-cell capacity, rapid decline in insulin secretion as well as visceral and …
Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as highly effective therapies for obesity and type 2 diabetes by improving glycemic control and reducing body weight, primarily through the suppression of energy intake. Recent evidence suggests …
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce major adverse cardiovascular events, all-cause mortality, and systemic inflammation in randomized controlled trials, with effect sizes exceeding those predicted from glycemic and weight-related improvements alone. The convergence of …
Background: GLP1 receptor agonists (GLP1RAs) and SGLT2 inhibitors (SGLT2Is) have established cardiovascular benefits for patients with type 2 diabetes mellitus (T2DM), with similar class-level effectiveness found in previous studies. However, real-world comparative effectiveness assessments of …
INTRODUCTION: GLP-1 receptor agonists (GLP-1RA) are glucose- and body weight-lowering therapies provided with cardio-renal benefits. Use of GLP-1RA in older adults with type 2 diabetes mellitus (T2DM) is increasing but concerns remain about their safety …
INTRODUCTION: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are widely used for weight management and type 2 diabetes, but reports of reduced skin laxity and volume have raised aesthetic concerns. This study evaluates the first …
Different types of dietary restriction (DR) have been practiced by humans for religious and medical purposes for millennia, but only during the past three decades has the scientific study of DR at cellular and molecular …
Drugs like semaglutide (a.k.a. Ozempic/Wegovy) that activate the glucagon-like peptide-1 receptor (GLP-1R) are a promising therapy for obesity and type 2 diabetes (T2D). Animal studies suggest that these drugs likely function by stimulating GLP-1R on …
Researchers found that turning off autophagy genes in C. elegans produces wildly different effects on lifespan depending on temperature, which specific gene is turned off, and other lab conditions. This suggests autophagy's role in aging …
Researchers analyzed 5.15 million people with type 2 diabetes across multiple countries to see if four common second-line diabetes drugs worked differently in women versus men. They found no sex differences in heart protection, but …
INTRODUCTION: Increased global lifespan is paralleled by a rise in non-communicable diseases with osteoarthritis and dementia, including Alzheimer's disease, impacting all nations with severe disability, death, and financial burden. AREAS COVERED: Given that osteoarthritis and …
The number of patients taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) is increasing. Beyond diabetes and weight management, these medications have various effects within the head and neck with both beneficial and potentially adverse clinical implications. …
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have expanded from metabolic therapeutics to agents with broad effects on inflammation, tissue repair, cutaneous and adipose biology, and aging-related pathways. Clinicians increasingly encounter cutaneous manifestations and aesthetic sequelae …
Glucagon-like peptide-1 receptor agonists, including long-acting semaglutide, are transformative anti-obesity therapies. However, emerging evidence indicates that weight loss may come at the expense of skeletal muscle mass, a tissue essential for mobility, metabolic regulation, and …
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed metabolic care but are increasingly associated with rapid, region-specific facial volume loss, commonly referred to as "Ozempic face." Current literature remains descriptive and largely focused on …
Individuals who carry two copies of the apolipoprotein E {epsilon}4 (APOE {epsilon}4) allele are at high risk of developing Alzheimer's disease (AD), yet the effects of APOE {epsilon}4 homozygosity on biological pathways related to AD …
Southern European countries have some of the highest life expectancies in the world, yet they display relatively high frailty. We examined different diets to identify compositions that promote both healthspan and strength in mice. The …
Myostatin and growth differentiation factor 11 (GDF11) are closely related members of the transforming growth factor-β superfamily (TGF-β) that negatively regulate skeletal muscle growth. Pharmacologic inhibition of myostatin has been shown to preserve lean mass …
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the management of type 2 diabetes and obesity. Due to class-wide reduction in major adverse cardiovascular events in cardiovascular outcome trials and pleiotropic actions in multiple tissues, the …